MedTrace Logo

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

Conditions

Interventions

DRUG

Pasritamig

Pasritamig will be administered.

DRUG

Cetrelimab

Cetrelimab will be administered by intravenous infusion.

DRUG

Cabazitaxel

Cabazitaxel will be administered by intravenous infusion.

DRUG

Docetaxel

Docetaxel will be administered by intravenous infusion.

DRUG

Apalutamide

Apalutamide will be administered orally.

DRUG

Enzalutamide

Enzalutamide will be administered orally.

DRUG

Darolutamide

Darolutamide will be administered orally.

DRUG

Abiraterone acetate plus prednisone (AAP)

Abiraterone acetate plus prednisone (AAP) will be administered orally.

DRUG

Lutetium Lu-177 vipivotide tetraxetan

Lutetium Lu-177 vipivotide tetraxetan will be administered intravenously.

DRUG

JNJ-101556143

JNJ-101556143 will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-26
Primary Completion
2027-08-31
Completion
2028-05-23
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05818683 on ClinicalTrials.gov